Navigation Links
INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:3/18/2009

filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. Arpida Interim Results for six Months to 30 June 2007
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
5. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
6. IsoTis Reports Interim Results of Vote for Integra Merger
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
10. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
11. VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 GMO corn cases filed across ... are in the process of being consolidated in a ... is In Re: Syngenta AG MIR 162 Corn Litigation, ... the District of Kansas. , Management of the Syngenta ... to U.S. District Judge John W. Lungstrum.* , As ...
(Date:12/24/2014)... December 23, 2014 According to Ross Selinger, ... Affiliate of ITRA Global, the national office market continues to ... This is evidenced by the third quarter’s surprising 3.9% ... Low energy costs have held inflation down and the ... is the housing market remaining soft. , This solid economic ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Pipette.com announces ... their Twitter followers can submit their #HolidayInTheLab pictures for ... their lab mates. , For those struggling to think ... the Pipette.com Holiday in the Lab Contest provides the ... Twitter followers to send pictures of their chemistree, ...
(Date:12/24/2014)... 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR ... December 22, 2014, thereby completing the U.S. HSR ... acquisition of the Company by Merck KGaA, Darmstadt, ... another condition to closing the transaction, which remains ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... Detecting Ovarian Cancer Earlier FRANKLIN LAKES, N.J. and MALVERN, ... (NYSE: BDX ) and Fujirebio Diagnostics, Inc., ... supply agreement for oncology diagnostic assays. Under the ... incorporate Fujirebio Diagnostics, cancer biomarkers for use on BD,s ...
... 4 Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; ... the Chief Scientific Officer of its Pulmo Science Inc. ... to present a paper at the 5th International Symposium ... in Quebec, Canada from June 26th to 29th. ...
... Inc. (NYSE Amex: NBS ), which is ... adult stem cells for future medical need, announced today ... worldwide rights to an innovative product and procedure using ... of chronic wounds. The licensed technology, with pending patent ...
Cached Biology Technology:BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 2BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 3BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 4Pulmo BioTech Inc. Announces Paper to be Presented at Symposium 2Pulmo BioTech Inc. Announces Paper to be Presented at Symposium 3NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds 2NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds 3
(Date:12/22/2014)... DENVER , Dec. 22, 2014  The ... for the biometrics industry as Acuity Market Intelligence ... biometrics may finally be open. Acuity forecasts that ... mobile devices that incorporate biometrics will drive a ... 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... 2014 The Defense Logistics Agency is ... detect and prevent counterfeit microcircuits from entering into ... started performing an in-house microcircuit anti-counterfeit initiative dubbed ... of purchased microcircuits while increasing their reliability throughout ... will be conducted at DLA,s Electronics Product Test ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... Asheville, N.C. May 1, 2008 There have been ... and the dairy industry has hyped the assertion by investing ... of the evidence published in the journal Nutrition Reviews reveals ... Amy Joy Lanou of the University of North Carolina ...
... HOUSTON (May 2, 2008)As the westernization of India accelerates, ... use by urban Indian children as young as 11, according ... School of Public Health. , The study, Associations Between ... published in the May/June issue of the American Journal of ...
... have discovered a new mechanism of infection for the ... only infectious disease which can kill entire colonies of ... economic loss to beekeepers all over the world. The ... The mechanism of infection (pathogenic mechanism) was originally ...
Cached Biology News:UT researchers find link between advertising and increased tobacco use among India's youth 2UT researchers find link between advertising and increased tobacco use among India's youth 3Bees disease -- 1 step closer to finding a cure 2
Mus musculus MARCKS-like protein, mRNA...
... from BRAND adds ergonomics and ease-of-use ... only electronic, motor-driven repeating pipette compatible ... BRAND PD-Tip syringe tips, Eppendorf Combi-Tips ... VWRbrand Combi-Syringes. Select virtually any pipetting ...
... can be used for efficient, mild and ... for ELISA or other assays for protein ... are bound with high efficiency to the ... will not elute during the assay due ...
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: